|
Jun 17
|
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
|
|
Apr 3
|
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
|
|
Feb 28
|
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
|
|
Jan 16
|
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
|
|
Dec 19
|
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
|
|
Dec 4
|
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
|
|
Aug 7
|
Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023
|
|
Apr 26
|
Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease
|
|
Apr 24
|
Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV
|